Other Current Assets

As of December 31, 2025 and 2024, other current assets were comprised of the following (in thousands):


	December 31,
	2025		2024
Prepaid services	$	797	$	87
Deferred costs (Note 7)		394		436
Prepaid insurance		543		559
	$	1,734	$	1,082

Property and Equipment, net

As of December 31, 2025 and 2024, property and equipment, net, were comprised of the following (in thousands):


	December 31,
	2025			2024
Office and computer equipment	$	1,782		$	1,778
Leasehold improvements		1,810			1,810
		3,592			3,588
Less accumulated depreciation		(3,335	)		(3,140	)
	$	257		$	448

Depreciation expense totaled $0.2 million and $0.6 million for each of the years ended December 31, 2025 and 2024, respectively.

As of December 31, 2025, intangible assets included the net book value of costs incurred for the purchase of Biocept intellectual properties (Note 12) and software upgrades. Amortization expenses totaled $0.1 million for each of the years ended December 31, 2025 and 2024.

As of December 31, 2025 intangible assets, net, were comprised of the following (in thousands):


	December 31,
	2025			2024
Software	$	221		$	221
Less: Accumulated amortization		(218	)		(218	)
Intellectual Property		546			546
Less: Accumulated amortization		(216	)		(80	)
Total intangible assets, net	$	333		$	469

As of December 31, 2025, future amortization expense on intangible assets is estimated to be as follows (in thousands):


Year Ending December 31,	Amount
2026		136
2027		136
2028		61
Total future amortization expense	$	333

Accounts Payable and Accrued Expenses

As of December 31, 2025 and 2024, accounts payable and accrued expenses were comprised of the following (in thousands):


	December 31,
	2025		2024
Accounts payable	$	3,276	$	9,474
Accrued payroll and bonus		993		920
Accrued professional fees		183		236
Accrued vacation and compensation		421		356
Accrued R&D studies		112		185
Accrued interest		—		117
Accrued other		935		—
	$	5,920	$	11,288